From Cancer Tests to Combat Drones: Mainz Biomed's Radical Reinvention Nears a Key Vote

Former diagnostics firm Quantum Cyber N.V. files patent for amphibious autonomous vehicle, seeks shareholder approval for defense pivot amid 540% stock surge.

The transformation playing out at what was once Mainz Biomed ranks among the most abrupt pivots in recent biotech history. The company, which built its name on molecular diagnostics for colorectal cancer, is now pursuing a future in quantum cybersecurity and autonomous military vehicles. Shareholders will get their chance to formally approve or reject the shift at a June 29 meeting in Amsterdam.

The newly renamed Quantum Cyber N.V. — trading under the Nasdaq ticker QUCY since March 2026 — has already taken concrete steps into the defense sector. On May 20, the company filed a provisional patent application with the US Patent and Trademark Office for a platform dubbed SCOUT-AX6 GUARDIAN. Invented by Jacob Gitman, the six-wheeled, electrically powered amphibious vehicle is designed for autonomous operations across land and water, with a particular emphasis on GPS-resilient navigation — a capability that addresses growing threats from jamming and spoofing on the modern battlefield.

The patent filing gives Quantum Cyber a 12-month window to submit a non-provisional application if it wants to secure full patent rights. Until then, the scope of protection remains limited. The timing lines up with a broader push by the US Department of Defense, which has requested roughly $55 billion in its fiscal 2027 budget for drones and autonomous warfare systems.

The upcoming shareholder meeting will decide on eleven resolutions, including a formal change to the company's articles of association that would allow the board to invest in quantum-capable autonomous defense platforms. The management plans to expand into post-quantum cryptography through further acquisitions, and will wind down the colorectal cancer screening business entirely, retaining only the pancreatic cancer diagnostics operation. Notably, the company has yet to report any customers or revenue tied to the new strategy.

Investor sentiment has been wildly volatile in the meantime. The stock closed on Friday at $3.33, giving the company a market capitalization of nearly $42 million. Despite the modest absolute price, the shares have surged more than 540% over the past month. The chart shows extreme swings: the year high of $4.93 sits as a formidable resistance level, while the Friday intraday low of $3.30 marks the nearest support. Adding to the uncertainty, the board is also seeking broad authority to issue new shares, putting the capital structure firmly on investors' radars.

The countdown to clarity is underway. The record date for voting rights is June 1, with official proxy materials to follow shortly after. When shareholders gather in Amsterdam on June 29, they will decide whether this radical transformation — from lab diagnostics to battlefield autonomy — moves forward or stalls.